SYMBION DIVIDEND COULD TAKE MONTHS

A A

THE Symbion Health board will meet early next week to consider an in-house report on whether it can pay its shareholders a dividend this financial year. The domestic healthcare company is part of the former Mayne Group, which split last Friday and on Monday started trading under the names Symbion and Mayne Pharma. Based on an accounting treatment under the terms of the demerger, Symbion must underwrite Mayne Pharma's share if the 10-day weighted average price falls below $2.60, thereby preventing Symbion paying its shareholders a dividend.

The Australian (http://www.theaustralian.news.com.au/common/story_page/0,5744,17430473%255E643,00.html)